首页> 外国专利> INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO

INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO

机译:炎症性肠疾病干细胞,靶向IBD干细胞的代理商及其相关用途

摘要

The present invention addresses IBD from the standpoint of mucosal stem cells cloned from defined regions of the gastrointestinal tract. In the case of pediatric Crohn's disease, for example, isolation of those stem cells according to the methods of the present invention reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.
机译:从从胃肠道的限定区域克隆的粘膜干细胞的观点,本发明解决了IBD。例如,在小儿克罗恩氏病的情况下,根据本发明的方法分离那些干细胞揭示了在回肠和结肠末端的干细胞中炎性基因表达的模式,尽管在大肠杆菌中连续培养了数月,但仍在表观遗传上得以维持。没有免疫细胞或基质细胞,或肠道微生物。在该分布的炎症表型上叠加了分化缺陷,其显着且特异性地改变了末端回肠的粘膜屏障特性。在克罗恩病患者的同一内窥镜活检中,病变干细胞与正常干细胞的共存意味着在这种情况下,粘膜干细胞之间存在表观遗传学上的强制异质性。

著录项

  • 公开/公告号US2020157495A1

    专利类型

  • 公开/公告日2020-05-21

    原文格式PDF

  • 申请/专利权人 TRACT PHARMACEUTICALS INC.;

    申请/专利号US201816611018

  • 发明设计人 FRANK MCKEON;MATTHEW VINCENT;

    申请日2018-05-07

  • 分类号C12N5/071;G01N33/50;A61K47/68;C12Q1/6883;

  • 国家 US

  • 入库时间 2022-08-21 11:23:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号